Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Non-cash Items (2022 - 2025)

Historic Non-cash Items for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $4.5 million.

  • Phathom Pharmaceuticals' Non-cash Items fell 9128.67% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year decrease of 9128.67%. This contributed to the annual value of $2.1 million for FY2024, which is 8605.88% down from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Non-cash Items stood at $4.5 million for Q3 2025, which was down 9128.67% from $4.4 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' Non-cash Items' 5-year high stood at $52.3 million during Q1 2022, with a 5-year trough of $2.1 million in Q3 2023.
  • In the last 4 years, Phathom Pharmaceuticals' Non-cash Items had a median value of $4.5 million in 2022 and averaged $17.3 million.
  • In the last 5 years, Phathom Pharmaceuticals' Non-cash Items tumbled by 9510.58% in 2023 and then soared by 238682.14% in 2024.
  • Quarter analysis of 4 years shows Phathom Pharmaceuticals' Non-cash Items stood at $4.5 million in 2022, then skyrocketed by 241.82% to $15.3 million in 2023, then plummeted by 86.06% to $2.1 million in 2024, then skyrocketed by 110.81% to $4.5 million in 2025.
  • Its Non-cash Items was $4.5 million in Q3 2025, compared to $4.4 million in Q2 2025 and $3.6 million in Q1 2025.